Key result
Carperitide during cardiac surgery linked to ~89% lower hospital mortality in hemodialysis patients.
Why the study?
Cardiac surgery in hemodialysis patients has increased but is associated with high mortality, and the efficacy of carperitide in this population is unclear.
Cohort (n=128)
No
Answers are grounded in this paper and cite their sources.
May support carperitide in hemodialysis patients undergoing cardiac surgery; leaves open need for prospective RCTs before practice change.
PURPOSE: Recently, performance of cardiac surgery in hemodialysis patients has increased, but the mortality rate is high. METHODS: We retrospectively examined the early and long-term outcomes in 128 dialysis patients who underwent cardiac surgery with or without carperitide infusion and were followed for 2 years. Sixty-three patients received carperitide infusion during surgery and 65 patients did not. RESULTS: The hospital mortality rate was 1.6% in the carperitide group and 12.3% in the non-carperitide group, being significantly lower in the carperitide group. The 2-year actuarial survival rate was 90.5% ± 3.7% in the carperitide group, and 76.9% ± 5.2% in the non-carperitide group, while the major adverse cardiovascular and cerebrovascular events (MACCE)-free rate at 2 years postoperatively was 90.5% ± 3.7% in the carperitide group and 67.7% ± 5.8% in the non-carperitide group. CONCLUSIONS: These findings suggest that carperitide improves the early postoperative outcome in dialysis patients undergoing cardiac surgery, as has already been demonstrated in non-dialysis patients. An early postoperative cardioprotective effect of carperitide and improvement of renal function in oliguric patients might have contributed to this outcome. However, this was a retrospective study, so a prospective investigation is required to demonstrate the mechanisms involved. In addition, further evaluation of the long-term results would be desirable.
No takes yet. Share an insight, caveat, or question.
Sezai et al. (2016) conducted a cohort in Hemodialysis patients undergoing cardiac surgery (n=128). Carperitide vs. No carperitide infusion was evaluated on Early (hospital) mortality (OR 0.11, 95% CI 0.01-0.93, p=0.043). Carperitide infusion during cardiac surgery significantly reduced the hospital mortality rate to 1.6% from 12.3% in hemodialysis patients compared to no carperitide.
Synapse has enriched 10 related papers. Consider them for comparative context: